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ABSTRACT
Cost Outcomes for Major Depressive Disorder and Bipolar Disorder
Across Professional License Types and Modalities
Julia H. Jones
School of Family Life, BYU
Master of Science
The purpose of this study was to compare outcomes for patients with Bipolar Disorder or
Major Depressive Disorder based on severity of diagnosis. This study also compared
psychotherapy providers and therapy modalities on total cost, number of sessions, and dropout.
Our data set (N=136,439) came from Cigna, a national health care company. Results showed
significant differences by severity of diagnosis. The comparison of providers showed that
psychologists had higher costs and session numbers, while the other providers were not
significantly different. However, all providers successfully provided low cost treatment on both
MDD and BD. There is no support for the idea that one profession is more successful at
providing low cost treatment for MDD and BD. Family therapy did significantly better on all
outcomes except dropout rate when compared to individual or mixed (individual and family
sessions) therapy. It is a low-cost option when treating MDD and BD, regardless of severity.
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Cost Outcomes for Major Depressive Disorder and Bipolar Disorder
Across Professional License Types and Modalities
Major Depressive Disorder (MDD) and Bipolar Disorder (BD) are very common and can
be challenging to treat (Cheung & Dewa, 2007; Kessler et al., 2005). MDD ranges from mild,
single episodes to severe and recurrent episodes (American Psychiatric Association, 1994,
Diagnostic and Statistical Manual of Mental Disorders, 4th ed.). BD is less common, but also
ranges in severity and chronicity (4th ed.; DSM-IV; American Psychiatric Association [APA],
1994). Standard treatment for each disorder can vary based on severity of the presentation (Paris,
2014; Rubio-Valera et al., 2015; Zu et al., 2014), and therefore it is important to consider cost
when evaluating modalities or providers for treatment.
Both disorders bring a high cost to society through a decrease in quality of life (Guan,
Deng, Cohen, & Chen, 2011), time and money lost for missed work and decreased productivity
(Langlieb & Kahn, 2005), and the expense of receiving treatment (Lazar, 2014). The cost of
treatment affects what options patients have and whether they seek treatment at all (Han,
Hedden, Lipari, Copello, & Kroutil, 2015). Psychotherapy continues to be effective in treating
MDD and BP (Lejeune, 2011; Parikh et al., 2015; Weitkamp et al., 2014; West et al., 2014; Zu et
al., 2014). Low cost providers of psychotherapy are able to give successful treatment while
keeping costs low (Crane & Payne, 2011). How severity affects treatment cost or who provides
treatment for more severe disorders remains unknown.
Comparing outcomes for these disorders by severity, provider type, and modality can
answer important questions about cost of psychotherapy treatment. A 2013 study by Crane et al.
compared providers and modalities in evaluating cost in treating depression. They suggested that,
“An analysis of cost, recidivism, and cost-effectiveness by severity would provide more
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information as would an examination of the interaction between age categories, gender, and
diagnosis. More research is needed to answer questions about the conditions under which therapy
is most cost-effective for depression.” (Crane et al., 2013, p. 467). This study aims to examine
the effects severity of diagnosis has on cost outcomes for MDD and BD.
This study looked at outcomes of the six major psychotherapy providers in their
treatment of MDD and BD. The six major groups of providers are Marriage and Family
Therapists (MFTs), Medical Doctors and Doctors of Osteopathic Medicine (MDs and DOs),
Nurses (RNs), Professional Counselors (LPCs), Psychologists (PSYs), and Social Workers
(MSWs). These groups include biomedical providers (MDs and RNs) as well as traditional talk
therapy providers (MFTs, LPCs, PSYs and MSWs). These providers may have different
outcomes in treating MDD and BD, including different lengths of treatments and costs. Previous
studies have found that there are some significant differences in outcomes when comparing these
providers (Crane & Payne, 2011; Moore, Hamilton, Crane & Fawcett, 2011). This study will
expand existing research to find out if diagnosis severity leads to additional differences.
No known studies have looked at a comparison between these providers on the severity
of the diagnosis and cost to treat. This study sought to find if severity of MDD and BD affected
outcomes by provider type. We also compared outcomes for the treatment of these disorders by
psychotherapy type: family therapy, individual therapy, and mixed therapy (comprising a
combination of both family therapy and individual therapy).
Literature Review
The severity criteria for MDD and BD use specific requirements in the DSM. Many
people will experience MDD in their lifetime, and even mild forms can greatly affect patients.
One major concern is cost. The treatment options for MDD and BD vary in both cost and
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outcomes, with family therapy showing particular promise. However, there are many different
licensed providers who treat MDD and BD with family therapy and it can be hard to compare
these options. Research is starting to show that some providers may have lower cost to treat than
others, perhaps even for severe forms of MDD and BD.
MDD and BD Diagnosis
Specific criteria must be met for a diagnosis of MDD or BD, and severity is based on the
number of symptoms as well as how much they interfere with functioning. MDD is a very
common condition, with BD being less common but they share a similar trajectory of depressive
symptoms. Both disorders affect patients and their families, including through the financial
burden for treatment.
DSM-IV diagnosis criteria and specifiers. Since a major component of this study
involves severity rating, it is important to understand what qualifies as mild, moderate or severe
ratings. Major depressive disorder consists of symptoms that indicate a major depressive episode
(4th ed.; DSM-IV; APA, 1994). Bipolar disorder is having a manic or mixed episode, which
could include a depressive episode (4th ed.; DSM-IV; APA, 1994). The number of symptoms
determines severity. Mild severity has fewer symptoms (the number depending on the type of
episode that was most recent) that only mildly interfere with daily functioning or normal
functioning but with unusual effort. Moderate severity is for ratings of symptoms that fall
between mild and severe. Severe without psychotic features requires having most of the listed
symptoms in excess to diagnosing and that are clearly observable or that markedly interfere with
functioning. Severe with psychotic features adds to the above with symptoms of delusions or
hallucinations that usually are consistent with the depressive themes (4th ed.; DSM-IV; APA,
1994). For manic and mixed episodes, a severe diagnosis is for patients who require “almost
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continual supervision required to prevent physical harm to self or others,” (4th ed.; DSM-IV;
APA, 1994, p. 379). Psychotherapy providers made the determination of severity and recorded
the code with severity specifier in the Cigna data set.
Occurrence rates. Most mental health providers will encounter clients with a diagnosis
of MDD or BD. Because of how prevalent they both are, a large portion of money spent on
psychotherapy goes into treating depression. Lifetime prevalence of MDD is estimated to be
16.6% to 21.4% and for BD 2.2% to 3.9% (Kessler et al., 2005; Lejeune, 2011; Perala, et al.,
2007). Patients who are 30-44 have the highest rates of MDD, whereas BD has higher rates for
ages 18-29 (Kessler et al., 2005). Females have higher rates of MDD than males and severe cases
are more prevalent than mild or moderate (National Institute of Mental Health, 2013). The
number one reason adolescents cited for why they were receiving mental health services was
“felt depressed” (56.5%; Han et al., 2015). Depression is a serious and common mental health
concern.
Impact. Along with financial consideration, MDD and BD cause other problems for
clients that lead to indirect costs. Major depression is associated with decreased physical and
mental health outcomes following diagnosis (McCusker et al., 2007). Depression links with
couple relational problems, parenting problems, and other severe stressors (Beach & Whisman,
2012). Symptoms from BD can affect the patient’s other relationships as well, including
marriage, children and occupation. It also leads to significant impairment in functioning and
well-being (Zarate, Tohen, Land & Cavanagh, 2000). Onset often happens in the late teens to
early twenties, a time already greatly impacted by transitions from moving out of the home, to
starting college or a first job, which adds further stressors to an already challenging time of life
(Lejeune, 2011). These indirect costs make it more important to have low cost treatment.
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Costs and usage. While cost is an issue in treatment, some positive findings justify
treatment costs. Adding psychotherapy to the treatment of BD does not necessarily add any cost
because of reductions in other expenses (Miklowitz & Scott, 2009). For example, those who
participated in group sessions were more likely to attend scheduled outpatient appointments, and
therefore didn’t need more expensive emergency visits. Even programs that may have a higher
cost initially usually are offset by other reductions, like fewer hospital stays and higher work
functioning, and often have better results of symptom reduction and relapse rates (Miklowitz &
Scott, 2009). The same is true for MDD—psychotherapy treatments are often lower cost than
medication treatment even when both have similar outcomes (Sava, Yates, Lupu, Szentagotai &
David 2009).
However, high costs can be a barrier to seeking treatment. In a survey of reasons why
patients with unmet mental health care needs did not receive mental health services in the past
year, “could not afford cost” was cited as the number one reason (45.4% of respondents; Han et
al., 2015). Other financial reasons for not receiving treatment included “health insurance did not
cover enough treatment” (9.1%) and “health insurance did not cover any treatment” (5.7%; Han
et al., 2015). For clients paying out-of-pocket, cost will be a very important factor.
One study showed that around 40% of patients with major depression had not used any
mental health services (Cheung & Dewa, 2007). Another reported that only 44.7% of those with
any mental illness and 68.5% of those with serious mental illnesses had received treatment (Han
et al., 2015). In addition, of those with serious mental illnesses, 46.3% reported an unmet need
for mental health care (Han et al., 2015). It appears that cost is a barrier to treatment, and
therefore identifying low cost providers could help with filling the unmet mental health care need
reported by so many suffering from mental illnesses.
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Comparing Severity
Patient outcomes vary by severity so examining them separately is important. Severity
can affect key variables in measuring cost, such as dropout rates and number of sessions for
more treatment for the same disorder. In addition, some studies show that severity of the disorder
can affect what treatment options are recommended (Paris, 2014; Rubio-Valeria et al., 2015)
from medications to traditional psychotherapy or alternative methods like shock therapy. There
is even disagreement on the nature and causes of MDD between severe ratings of mild or
moderate (Paris, 2014) leading to conflict about the best course of treatment for severe MDD.
This confusion could make it challenging for those seeking help. Doctors prescribe medication
for severe cases, but psychotherapy can also be helpful even for severe depression (Paris, 2014).
These findings illustrate why it is important to consider severity to provide clarity for patients.
There is some evidence that the severity of a disorder can affect dropout rates. Johansson
and Eklund (2006) revealed a moderate effect between problem severity and helping alliance,
which in turn affected dropout rates. For depression, specific interventions make a bigger
difference than therapist or client variables (Swift & Greenberg, 2014). When considering why
severity or diagnoses might affect dropout, it may be that some clients most in need of treatment
drop out of therapy, or that they do not like the treatment offered (Bischoff & Sprenkle, 1993).
Having a chronic problem can increase the chance of dropout because they are harder cases to
treat (Lazar, 2014). This study may help reveal whether some providers can mitigate higher
dropout rates for severe cases.
Treatments
Medications are often the first line of treatment for both MDD and BD. While common,
there are some disadvantages to solely relying on medication for most patients. Another option is
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psychotherapy, which has been extensively studied with these disorders and has been shown to
be effective in many cases. Research on family therapy in particular reveals positive outcomes
and is increasingly utilized to treat these disorders, with successful results for symptom reduction
and at a low cost to patients.
Limits of medications. Psychotropic drugs are the standard treatment for MDD
(Gartlehner et al. 2016; Rubio-Valera et al., 2015). Protocol of prescribing medication for MDD
is often based on severity, with fewer prescriptions recommended for mild forms (Rubio-Valera
et al., 2015). The consideration of other treatments can be beneficial however, because some
research suggests that drug treatments do not necessarily lead to long-term success or remission.
Gartlehner et al. (2016) found that patients treated with medication had similar benefits but
greater risks than those using psychological, complementary and alternative medicine (CAM)
options or exercise interventions.
Many types of treatment can be effective for the various phases of BD including
medication, psychoeducation, and therapy (Lejeune, 2011). Particularly with pediatric patients
though, medication can have low response rates and tolerance problems (West et al., 2014).
Incorporating psychosocial interventions can improve outcomes, and increase effectiveness and
overall treatment response better than medications alone for the treatment of BD (Fristad &
MacPherson, 2014; Parikh et al., 2015). For families with high impairment, psychosocial
treatments can have even greater impact on improving symptoms (Miller et al., 2008).
Medication is usually always a part of treatment for BD, but incorporating other methods makes
treatment more effective.
Psychotherapy. Psychotherapy is a common treatment for MDD and BD (Lejeune,
2011). Psychotherapy can significantly improve severe depressive symptoms for children and
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youth as well (Weitkamp et al., 2014). This is an important point, because “felt depressed” was
cited as the number one reason youths aged 12 to 17 sought specialty mental health treatment
(Han et al., 2015). Research on treatment effectiveness in this population addresses a key
disorder in adolescent mental health problems.
Many clients report a preference for psychotherapy over medication in treating
depression, despite the increase in pharmacotherapy treatment (Kuramoto-Crawford, Han,
Jacobus-Kantor & Mojtabai, 2015). This difference may be more indicative of what providers
are offering as treatment rather than patient choices. Psychoeducation, cognitive-behavioral
therapy, family-focused therapy and interpersonal and rhythm therapy are standard treatments
beyond medication (Lejeune, 2011). As clients learn treatment is effective, these preferences for
psychotherapy may continue to increase.
For moderate to severe MDD, CBT can be effective, even when compared to medication
alone (Zu et al., 2014). There is some evidence that psychosocial treatment helps improve BD
symptoms in children and adolescents. However, there is not enough research and too small of
sample sizes to be definitive (Fristad & MacPherson, 2014). This highlights the need for research
on psychotherapy effects with BD.
Family therapy. Family therapy can be more effective than individual treatments for
MDD and BD (Carr, 2014a, 2014b; Crane et. al., 2013; Pinsof & Wynne, 1995; Shadish et al.,
1995; Stratton, Silver, Nascimento, McDonnell, Powell & Nowotny, 2015). Marital therapy
alleviates depression and delays relapse, even when there is also concurrent marital discord
(Carr, 2014a). These outcomes are likely a result of increasing family support for the person with
depression and decreasing stress and conflict. For BD, patients were three times more likely to
remain in remission without relapse when receiving family-focused therapy combined with
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pharmacotherapy compared to those receiving crisis management and pharmacotherapy
(Miklowitz & Scott, 2009). Further, those who received family-focused therapy had lower
remission rates compared to those receiving individual therapy at 1-2 year follow-up (Miklowitz
& Scott, 2009). This is probably due to the fact that family therapy has benefits to other family
members in addition to the identified patient.
Child- and family-focused cognitive behavioral therapy (CFF-CBT) is more effective for
pediatric BD than treatment as usual (West et al., 2014). Family therapy treatment for BD
especially helps when there are high levels of impairment. It leads to significantly improved
course of illness and number of depressive episodes (Miller et al., 2008). These findings
demonstrate the possibility that family therapy is particularly effective when there are severe
symptoms.
Cost of family therapy. Total health care use in all areas is highest for patients who
receive individual therapy rather than family therapy (Law & Crane, 2000). In a study that used a
number of diagnoses, including MDD and BD, patients who received only family therapy
required the fewest number of sessions compared to those who received individual or mixed
therapy with family and individual treatment (Crane & Payne, 2011). These results are also true
for depression specifically (Crane et al., 2013). This study will see if severity affects the cost of
family therapy.
Family therapy is affordable because it provides services to more people for the price per
session, sometimes referred to as a “multiplier effect” (Fals-Stewart, Yates, & Klostermann,
2005). Therapists work to make changes in the family system so that all members are helped, and
the presenting client will return to an environment that has been improved from family therapy.
It can reduce the need for expensive social or health services, and can allow family members
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return to employment, hold a job, or operate a more profitable business (Fals-Stewart et al.,
2005). Since MDD and BD affect the whole family (Beach & Whisman, 2012; Zarate, Jr. et al,
2000) this effect may be very important and can affect cost as well as outcome and long term
gains for the patient.
Comparing Providers
The mental health field is expanding, and this means that there are a number of different
licenses and practitioner types who provide psychotherapy treatment. Patients have some control
over who they choose to see for this treatment, and as they learn more about the varying
specialties they seem to indicate some preferences. Research comparing the professions shows
that there are some differences between providers, including with cost.
There are few studies conducted that have examined profession and cost of treatment
measures previously (Crane & Payne, 2011; Moore et al., 2011). The six types of providers that
we will be looking at for this study are nationally regulated with professional organizations.
These providers are Marriage and Family Therapists (MFTs), Medical Doctors and Doctors of
Osteopathic Medicine (MDs and DOs), Nurses (RNs), Professional Counselors (LPCs),
Psychologists (PSYs), and Social Workers (MSWs). They are from programs with accredited
training standards and stringent licensing requirements in all 50 US States (Crane et al., 2010).
These regulations, standards and requirements established qualifications across the mental health
disciplines that make them comparable in delivering mental health treatment. As some have
examined the differences among state licensure laws, they found that there is not a lot of
difference in the varying professions’ “scopes of practice” to provide mental health services
(Hartley, Ziller, Lambert, Loux, & Bird, 2002). For this reason, it is appropriate to compare them
for the purposes of this study.
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Patient choices. Patients diagnosed with depression reported more helpfulness from
treatment by specialty mental health providers than general practitioners alone and these findings
remained even when accounting for other moderating factors (Kuramoto-Crawford et al., 2015).
MFT may be less expensive than services provided by other professionals, such as MDs/DOs
and PSY, without sacrificing positive outcomes like low dropout rates (Law, Crane & Berge,
2003). Providers who specialize in family therapy may be preferred over those who do not.
For adolescents with a major depressive episode, 20% reported that they saw or talked to
a medical professional, 2.8% reported only using medications, and 16.4% reported using
medications and talking to a medical professional (Han et al., 2015). Male adolescents with
MDD were most likely to go to psychiatrists for service providers, whereas female adolescents
were more likely to go to a social worker or counsellor (Cheung & Dewa, 2007). However, of
young adults, men and women were more likely to visit general practitioners for treating MDD
(Cheung & Dewa, 2007). What is less known is what influences these choices.
A study on more severe disorders caution that comparing cost in these populations needs
to take into account that effective treatment can take longer. This means that long-term goals
need to be considered as well as shorter-term goals of reducing total charges (Lazar, 2014).
Because chronic and severe disorders are more challenging to treat (Lazar, 2014), identifying
which providers are able to reduce costs during this treatment is valuable. There are no known
studies indicating which psychotherapy providers are more affordable in treating disorders based
on severity.
Differences by profession. While only MFTs and some LPCs are required to specifically
study family therapy, other professions practice family therapy. Moore and associates (2011)
found significant differences in therapy outcomes for the different professions who practice
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family therapy when considering individual and family therapy together. MFTs ranked better
than other professions on dropout rates, but they keep patients for more sessions than the other
providers. Overall, MFTs are affordable providers for therapy (Crane & Christenson, 2014).
What we will find out is how severity may affect these outcomes for MFTs.
Other earlier studies looked into profession comparisons. In the most recent known metaanalysis of 91 studies, Chiles and associates (1999) explained that PSY, MSWs, and MDs did not
have significant differences in medical cost offset. They all reduced patient recovery time, which
decreased medical care use and cost savings. Another study also established that patients who
saw a MFT were just as likely to experience medical utilization reductions as if they saw a MD
or MSW. An analysis on age, gender and experience of the therapist did not identify any
differences. Therapy reduces medical utilization expenses, but does not demonstrate a difference
between those three types of therapists (Crane, Wood, Law & Schaalje 2004). These are just
some of the early findings comparing providers.
More recently, a large study considered provider outcomes (Crane & Payne, 2011). When
examining number of sessions, the rank of lowest to highest sessions by profession was MDs,
RNs, LPCs, MFTs, PSYs, and MSWs. The average was 6.95 sessions across all provider types.
The ranking of low cost providers by profession was as follows: LPCs; MFTs, MDs and MSWs
(ranked tied with no differences between each other); RNs, and PSYs. They also discovered the
highest outcome success with MFTs, who had 86.6% success rate. The most affordable
profession was LPCs. MDs and MFTs followed, and MSWs, RNs and PSYs were least
affordable. When looking at who provides family therapy, MDs had a rate of 22.3% (N=6,408),
MFTs 17.4% (N=35,609), LPCs 17.1% (N=103,730), MSWs 12.5% (N=175,437), PSYs 12.5%
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(N= 163,273), and RNs 12% (N=5,192). While there are statistically significant differences in
costs by profession, psychotherapy provided by these providers are low cost treatments overall.
Providers differed on outcomes for depression (Crane et al., 2013). Ranking of overall
costs from lowest to highest was LPCs, MDs, RNs, MSWs, MFTs and PSYs. LPCs were the
most affordable and PSYs were the least. Those researchers also found that family therapy was
the most affordable modality. This study will add to previous research by considering the effect
severity will have on these outcomes, as well as the results for a diagnosis of BD of differing
severity levels.
Current Study
While previous research lays the groundwork to explore cost of treating MDD and BD by
comparing providers, there is still a lack in the literature addressing these concerns when it
comes to the severity of diagnosis. This study investigated whether different types of providers
were effective in providing services for severe diagnosis versus those with mild and moderate
severity of MDD and BD. We compared the six major mental health providers—MFTs, MDs
and DOs, RNs, LPCs, PSYs, and MSWs—using number of sessions, total cost, and dropout rate.
We also compared the differences between biomedical providers (MDs and RNs) and talk
therapy providers (MFTs, LPCs, PSYs and MSWs).
Research Questions
1. Does severity of MDD predict cost, number of session, and dropout rate when controlling for
provider type, modality, age, gender, and region?
2. Does severity of BD predict cost, number of session, and dropout rate when controlling for
provider type, modality, age, gender, and region?

COST OUTCOMES FOR MDD AND BD

14
Method

Data for this project comes from Cigna, a national health insurance company. The sample
contains patients who received an MDD or BD diagnosis from 2001-2006. We used DSM-IV
(1994) 4th ed. diagnostic codes for analysis, and these codes include different numbers to
indicate severity ratings. Variables used in this paper were chosen based on the data available
from Cigna and allow for a cost analysis between the providers and modalities.
Design
This study was a retrospective study and used administrative data from Cigna, a
nationwide health care insurance manager in the United States. The Health Insurance Portability
and Accountability Act of 1996 (HIPAA) allows the use of un-identifying administrative data for
retrospective statistical analysis. These data do not provide unique subscriber or provider
information. Records available for each patient include: unique identification number, age,
gender, treatment date, state where the visit took place, current procedural terminology code
(CPT)—which was either 90806 individual psychotherapy 45-50 minutes or 90847 family
psychotherapy—, primary DSM-IV (1994) 4th ed. diagnosis, therapist license type, highest
degree earned by therapist, dollar amount of claim, and number of sessions or visits per claim
(Crane & Payne, 2011). The data were cleaned to eliminate less common provider types,
unknown licenses, and secondary licenses. For a full explanation of the original data set and data
cleaning procedures, see Crane and Payne (2011).
Sample
The sample (n=136,439) contains individual patients who had received psychotherapy
treatment for Major Depressive Disorder or Bipolar Disorder between 2001 and 2006. This
information comes from a larger data set. For MDD (n = 128, 688) ages of participants ranged
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from 0 to 96 (M =37.24, SD=14.01), with 3,127 (2.43%) children (0-12), 15,999 (12.43%) teens
(13-19), and 109,562 (85.14%) adults. There were 88,939 females (69.11%) and 39,584 males
(30.76%), with 165 (0.13%) where gender was not reported. For BD (n = 7,751) ages ranged
from 3 to 85 (M = 35.83, SD = 14.29), with 274 (3.54%) children, 1,041 (13.43%) teens, and
6,436 (83.03%) adults. There were 5,052 (65.18%) females and 2,692 (34.73%) males, with 7
(0.09%) missing values. Participants were from all regions in the United States. No additional
demographic data were available.
Diagnoses
Major Depressive Disorder. The DSM-IV (1994) 4th ed. diagnostic codes for the mild
diagnosis are 296.21 and 296.31. Moderate codes are 296.22 and 296.32. Diagnostic codes for
severe without psychotic features are 296.23, and 296.33. Severe with psychotic features are
296.24 and 296.34. In all cases, a moderate diagnosis was the largest group (55.61%) followed
by severe without psychotic features (31.84%), mild (10.41%), and severe with psychotic
features (2.15%).
Bipolar Disorder. The DSM-IV (1994) 4th ed. diagnostic codes for mild BD are 296.01,
296.41, 296.51, and 296.61. Moderate BD codes are 296.02, 296.42, 296.52, and 296.62.
Diagnostic codes for severe BD without psychotic features are 296.03, 296.43, 296.53, and
296.63. Severe BD with psychotic features codes are 296.04, 296.44, 296.54, and 296.64. In all
cases, a moderate diagnosis was the largest group (45.57%) followed by both severe without
psychotic features (31.70%) and severe with psychotic features (13.77%), and smallest was mild
cases (8.97%).

COST OUTCOMES FOR MDD AND BD

16

Providers
We included six major therapy provider types for this study: Marriage and Family
Therapists (MFTs), Medical Doctors (MDs and DOs), Nurses (RNs), Professional Counselors
(LPCs), Psychologists, and Social Workers (MSWs). These were selected because of their
national recognition as independently licensed health care practitioners (Crane & Payne, 2011).
When a claim shows a provider with more than one license type, we used the license type listed
as “primary.”
Definitions of Variables
Episode of care. Cigna defines an episode of care (EoC) as a continuous series of
treatment for one patient. An episode of care ends 90 days after the last insurance claim form is
filed. The number of sessions in the first episode of care ranged from 1 to 203 (M= 4.54, SD=
5.668). This study used only the first episode of care for each patient.
Total cost. Total cost is defined as the total dollar amount paid by Cigna for all therapy
services during the first episode of care.
Dropout. Dropout is defined as a participant attending only one session of therapy and
then not returning for future services (Hamilton, Moore, Crane & Payne, 2011). While defining a
specific number of sessions as cutoff for dropout is usually an arbitrary decision (Bischoff &
Sprenkle, 1993), this definition is consistent with existing dropout literature (Allgood & Crane,
1991; Johansson & Eklund, 2006; Werner-Wilson & Winter, 2010; Wierzbicki & Pekarik, 1993).
A one-session cutoff will likely not overestimate the number of dropouts (Hamilton et al., 2011),
although for medical doctors who are more likely to have fewer sessions, it may have some
effect.
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Family therapy. Family therapy is identified in this study by Current Procedural
Terminology (CPT) code 90847, “Family psychotherapy (conjoint psychotherapy) (with patient
present)” (American Medical Association, 2006, p. 278).
Individual therapy. Individual therapy was identified in this study by Current
Procedural Terminology (CPT) code 90806, “an insight oriented, behavior modifying, and/or
supportive treatment in an office or outpatient facility, approximately 25 to 50 minutes face-toface with the patient” (American Medical Association, 2006, p. 277).
Mixed therapy. In this study mixed therapy is defined as an episode of care including
both sessions of family therapy and sessions of individual therapy. This definition does not
address the range of possible individual to family therapy ratios. For example, an episode of care
would be categorized as mixed if it consisted of 20 individual sessions and one family therapy
session, or if it consisted of one individual session and 20 family therapy sessions. Although, this
isn’t a perfect definition, this modality is incorporated in the study to represent the participant
experience that isn’t specifically individual or family therapy.
Results
We ran basic descriptive statistics for total cost, total sessions, and dropout rate for the
six provider types and the three modalities for all levels of severity. Mean total dollars was
$487.88 (SD=$734.14), with a median of $250 (range = $0.48 to $29,905). Mean total sessions
was 9.68 (SD=12.85), with a median of 5 (range = 1 to 339). Full descriptive values for MDD
are reported in table 1, and for BD in table 2. Data are skewed, but test regressions with logtransformed data did not affect results, thus it was decided to not use log transformations to
answer the research questions to aid in interpretation of the results. All regressions were run with
gender, age, and region as control variables.
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The first question examined severity differences in total cost, number of sessions, and
dropout rates for depression. For cost and number of sessions, we ran regressions using MFT as
the provider comparison group and family therapy as the modality comparison group.
The full model for cost to treat depression was significant F (16, 120,313) = 433.81, p =
0.00, R² = 0.05, All four severity groups showed significant differences. Severe with psychotic
features diagnosis had the strongest relationship to depression cost, followed by severe without
psychotic features, moderate, and finally mild. For the six professions, only psychologists had
higher costs that were significantly different from MFTs (b = 144.44, SE = 7.53). Both individual
therapy modality (b = 132.15, SE = 8.14) and mixed therapy modality (b = 455.41, SE = 9.38)
were significantly higher on total cost than family therapy modality. Gender, age, and region
were also all significant predictors of total cost.
Full results for number of sessions were significant F (16, 120,312) = 441.79, p = 0.00,
R² = 0.06. Severity and modality again showed the same patterns as cost. Provider type,
however, had some differences. MDs (b = -2.58, SE = 0.26) and RNs (b = -0.92, SE = 0.36) had
significantly fewer sessions than MFTs. MSWs (b = 0.33, SE = 0.14) and PSYs (b = 1.13, SE =
0.14) had significantly higher session number than MFTs. LPCs were not significantly different.
For dropout rates we ran logistical regressions. The overall model for dropout was
significant Χ² = 5928.53, p = 0.00, R² = 0.06. Only the diagnosis of severe without psychotic
features was significantly different from a mild diagnosis (b = -0.07, SE = 0.03). For provider
type, again only RNs and PSYs were significantly different from MFTs. RNs were slightly
higher (b = 0.13, SE = 0.08) and PSYs were slightly lower (b = -0.17, SE = 0.03). Both
individual and mixed modalities had significantly lower dropout rates than family therapy.
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Gender, age, and region were significant, except for the Western region. Results of the
regressions for MDD are in table 3.
The second question considered cost, number of sessions, and dropout rates for BD. This
again looked at severity groups, provider type and modality, while controlling for gender, age,
and region.
The results for total cost model was significant F (16, 7163) = 30.86, p = 0.00, R² = 0.06.
Both severe with psychotic features (b = 92.24, SE = 38.96) and severe without psychotic
features (b = 78.67, SE = 34.22) had significantly higher costs than mild or moderate diagnoses.
Only PSYs were significantly higher on cost than MFTs (b = 202.58, SE = 38.57). Individual (b
= 111.17, SE = 19.21) and mixed (b = 483.32, SE = 42.51) modalities were significantly higher
on cost than family therapy modality. Gender, age, and region were all significant as well.
Results for session number showed the overall model was significant F (16, 7163) =
33.82, p = 0.00, R² = 0.07. Again, both severe diagnoses were significantly different with higher
session numbers. MDs had significantly lower session numbers (b = -2.07, SE = 0.96) and PSYs
had significantly higher session numbers (b = 2.25, SE = 0.70) than MFTs. Individual (b = 2.49,
SE = 0.67) and mixed (b = 10.36, SE = 0.77) modalities had significantly higher session numbers
than family therapy. Gender, age, and region were significant, except for the South and West
regions.
Results of the logistic regression for dropout had Χ² = 527.83, p = 0.00, R² = 0.09. Severe
without psychotic features was significantly lower dropout rates than the other diagnoses (b = 0.36, SE = 0.13). MDs had a higher dropout rate than all other provider types (b = 1.31, SE =
0.18). Modality differences again had significantly lower dropout rates than family therapy.
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Gender was significant, while age and region were not, with the exception of the South and West
being significant. All results from the regressions for BD are found in table 4.
Discussion
This is the first known study to examine the effect that diagnosis severity had on cost
outcomes by provider types and modalities for MDD and BD. While there are many providers
who treat MDD and BD, patient choice is affected by cost to treat. Research already shows that
family therapy and MFTs are effective at improving symptoms for MDD and BD. The results of
this study show that they are also affordable options for patients seeking treatment, whether they
suffer from mild, moderate or severe diagnoses.
For MDD total cost and number of sessions, results varied by severity. The more severe a
case the higher the cost and number of session it takes to treat. Only psychologists were
significantly higher on both variables. Average total cost for psychologists was $579.34,
compared to $451.72 for marriage and family therapists, a savings of $127.62 for an episode of
care—which can lead to substantial savings across multiple cases. Number of sessions showed
several differences between the providers. Medical doctors and registered nurses had the lowest
number of session, followed by marriage and family therapists and counselors, and social
workers and psychologists with the highest number of sessions. The average session numbers
ranged from 6.38 (medical doctors) to 10.39 (psychologists). As each session will vary in cost
depending on the provider, these values directly affect total cost as well. For example,
psychologists have a higher average number of sessions, and therefore total cost will also be
higher. They may also be charging more per session, further inflating their total cost in
comparison to the other providers.
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Depression rated as severe without psychotic features (14.13%) had significantly lower
dropout rates compared to mild (14.29%). This is likely because those with severe depression
receive treatment at higher rates (Han et al., 2015). Medical doctors have the highest dropout
rate (30.76%). This seems to fit with the nature of medical treatment, where they may only see a
patient once to write a prescription and then that patient may not return for follow up
appointments. Thus, the measure of dropout may not be accurately capturing the unique structure
of medical providers compared to those who exclusively do psychotherapy. Interestingly,
psychologists had the lowest dropout rate (12.66%), while the others were in the middle with no
significant differences. So, although psychologists have more sessions and higher cost, they may
be better than other providers at retaining clients.
Comparing severity for BD reveals a split. For cost and number of session, both forms of
severe ratings are different from mild and moderate. Severe with psychotic features had an
average cost of $586.71 and average session number of 11.46, compared to mild at $473.46 for
cost and 9.35 for session number. Psychologists again had the higher rates of cost ($664.82) and
number of session (11.91). All other providers were statistically not significantly different from
each other, except MDs had significantly lower number of session than the others (6.66). The
only significant difference for dropout was MDs had higher rates as with MDD (38.52%). Given
the nature of medical care, it is possible that these results are showing the medication bias that
medical doctors may be turning to in treating MDD (Paris, 2014), where after receiving a
prescription patients may not feel the need to return for more sessions.
Results seem to indicate that all the professions can provide psychotherapy treatment for
MDD and BD in an affordable way and with few sessions (Crane & Payne, 2011). The idea that
one profession over another is more affordable at providing treatment for MDD and BD is not
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supported from these results. This means that when patients and insurance companies consider
what providers to visit or cover for treatment, there is no need to exclude certain types because of
cost concerns.
The comparison between modalities is much more straightforward. Family therapy is
significantly cheaper and requires significantly fewer sessions than both individual and mixed
modalities. Mixed therapy had the highest cost and total sessions. The range for total cost for
MDD was $250.82 for family therapy to $752.29 for mixed therapy. Average sessions have a
similar disparity ranging from 5.09 for family therapy to 15.32 for mixed therapy sessions. For
BD, cost ranged from $292.79 to $848.25, and sessions from 5.49 to 17.14. These larger ranges
for modality suggests a much stronger association with modality type and outcomes than when
comparing provider types. This is compatible with other literature that explains why the
“multiplier effect” of family therapy leads to reduced cost by treating multiple family members
at once and preventing the need for care outside of the now functioning family unit (Fals-Stewart
et al., 2005).
Only on the measure of dropout does family therapy have higher rates at 24.94% for
MDD and 29.50% for BD. This could be because having more than one person to schedule with
can make it harder to continue, or it can be challenging for multiple people to form an alliance
with the same therapist, which is an important factor that reduces dropout (Bischoff & Sprenkle,
1993). Individual therapy had better dropout rates than family (15.52% for MDD and 15.34% for
BD). Mixed therapy cannot be evaluated on dropout rate in the same way since the definition of
mixed therapy requires one individual session and one family session, whereas dropout is
defined as not returning after one session only.
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As cost to treat has been cited as a barrier to seeking treatment (Han et al., 2015), these
results indicate that family therapy is a low-cost option when treating MDD and BD, regardless
of the severity. This is similar to results in other studies for different disorders (Crane & Payne,
2011). This study adds to the literature on family therapy and further confirms the superior
affordability of this modality over other options.
Clinical Implications
Psychotherapy clinicians generally rely on an influx of patients to maintain their
professions. They frequently must balance offering low enough fees to attract patients while still
maintaining an income to support themselves and their business or employer. While
psychotherapy is still a growing field, there may be misconceptions as to which kinds of
providers are able to effectively and affordably treat MDD and BD. The results of this study
show that most of the major provider types can treat all severities of these disorders. There were
very few differences in cost, session number, and dropout when comparing provider types. This
means that some clinicians, such as MFTs, who are less often thought of as treating severe
mental conditions like MDD and BD, can also provide low-cost and effective treatment for
severe disorders.
Clinicians who provide family therapy may particularly find this study helpful in
supporting the systemic approach to treatment. Not only can family therapy more effectively
treat MDD and BD (Carr, 2014a, 2014b; Crane et. al., 2013; Pinsof & Wynne, 1995; Shadish et
al., 1995; Stratton, et al., 2015), but it can also provide that treatment as a lowest cost option and
for the fewest sessions of all the modalities.
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Limitations
This study adds support to the literature on cost outcomes. However, there are some
limitations to this study. The data used in this analysis is retrospective in nature. While it allows
for real world comparison, patients were not randomly assigned and therefore we were limited in
what we could controls we could use. The low rates of explained variance in this study indicate
that there are many other factors influencing cost, dropout, and number of treatment sessions. It
is unknown what therapy theories or methods providers used which could be affecting outcomes,
as some models are designed to be brief or allow for better alliance with the therapist.
There are many limitations to the way dropout was measured. There are no reasons given
about dropout rates, and therefore evaluating high dropout rates as negative may not be
completely accurate. This is a particular limitation for medical doctors, who are more likely to
have patients attend one session to receive medication prescriptions and then who may not return
for more care. Our data doesn’t allow us to know if patients were satisfied with these shorter
episodes of care or not.
We also do not know the client’s satisfaction with treatment or outcomes in reduction in
symptoms. While lower cost and session number seem like positive results, if patients do not get
better in their experience with MDD or BD it may not be effective treatment. The higher cost and
session number associated with psychologists could be explained by these other kinds of factors
not analyzed in this study. We were not able to measure how much each provider charges per
hour, a value that may greatly explain some of the variance. Conversely the low session numbers
but high dropout rates for medical doctors are likely due to factors we are not able to gather from
the data available.
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In regards to family or mixed therapy, information is not provided on which members of
the family attended therapy sessions with the identified patient. It is possible that there are
differences between marital versus family therapy but both types were included in the family
therapy code. While many people who are experiencing MDD or BD concurrently take
medications, there is not information in this data set on medication usage. While research shows
that psychotherapy can be more effective than medication (Miller et al., 2008), we do not know
what impact medication use may have had on symptom improvement, and thus reducing the
need for continued treatment. This could affect cost, session number, and even dropout rates.
Future Research
Cost is an important outcome that affects insurance companies and patients. However,
future studies could look at follow up outcomes to see if reduced cost holds true in the long term.
Some studies indicate that spending more at the onset leads to lower cost in the long term for
certain methods of treatment (Miklowitz & Scott, 2009).
Future research could focus on finding out what other factors affect the measures of cost,
session number and dropout rates. Analysis including information on what methods and models
are used by providers could be beneficial. While there has been disagreement in the literature on
how to measure dropout (Allgood & Crane, 1991; Johansson & Eklund, 2006; Werner-Wilson &
Winter, 2010; Wierzbicki & Pekarik, 1993), further study can continue to refine definitions to
account for the many facets of this variable.
Outcome researchers could include measures of cost, session number and dropout to
combine the effects these two important aspects have on each other. Continuing the comparison
between provider types and modalities would add clarity to this topic. It may also be useful to
look at marital therapy as a separate modality. Also, when studying disorders like MDD and BD
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that often are simultaneously treated with psychotherapy and mediation, it could improve the
results to measure medication use along with psychotherapy treatment.
Future research could look into answering why family therapy is more affordable.
Research could examine whether family therapy does well on other outcomes, such as
measurements of MDD or BD improvement in symptom severity and diagnosis. A qualitative
approach to the study of dropout and return to care could explain reasons for these rates by
modality and provider type.
Conclusions
This study sought to compare MDD and BD cost outcomes by severity. Cost and session
numbers were different based on severity for MDD and only for severe levels in BD. Dropout
was only different for severe disorders without psychotic features. The differences between
providers on the measured outcomes showed some significant differences, but many were within
a close range to each other. PSYs were higher on cost and session number, and MDs were lower
on cost and session number, but higher on dropout. Results showed that MFTs are able to
provide psychotherapy treatment for all severity levels of MDD and BD with low cost, session
number, and dropout rate. Family therapy modality had the best results on almost all measures.
This provides reason for patients, providers, and insurance companies to consider MFTs and
family therapy when treating MDD or BD.
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Table 1
Descriptive Statistics [Mean (SD)] by Modality, Profession and Severity for MDD
Avg Sessions

Avg Cost

Dropout

Indiv. (N=103,301)

9.01 (12.29)b

$457.56 ($715.27)b

15.52%a

Family (N=7,886)

5.09 (6.58)

$250.82 (350.29)

24.94%

Mixed (N=17,501)

15.32 (15.50)b

$752.29 ($846.77)b

N/A

MDs (N=2,799)

6.38 (10.07)a

$423.58 (668.69)

30.76%b

RNs (N=1,275)

8.65 (11.34)a

$465.86 ($641.54)

15.68%

PSYs (N=34,727)

10.39 (13.47)b

$579.34 ($804.57)b

12.66%a

LPCs (N=24,698)

8.53 (11.22)

$389.03 (581.52)

14.79%

MSWs (N=45,664)

9.64 (12.66)b

$444.65 ($648.60)

13.69%

MFTs (N=11,383)

9.47 (12.34)

$451.72 ($643.45)

13.95%

Mild (N=13,395)

9.00 (11.81)

$454.50 ($660.94)

14.29%

Moderate (N=71,560)

9.48 (12.43)b

$477.30 ($716.82)b

13.87%

Severe (N=40,969)

10.03 (13.52)b

$506.32 ($762.68)b

14.19%a

Severe w/(N=2,764)

10.22 (13.18)b

$514.84 ($769.89)b

15.30%

Total (N = 128,688)

9.63 (12.75)

$484.98 ($727.59)

14.04%

a

indicates a value significantly lower than the control groups (Family therapy, MFT and mild)

b

indicates a value significantly higher than the control groups (Family therapy, MFT and mild)
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Table 2
Descriptive Statistics [Mean (SD)] by Modality, Profession and Severity for BD
Avg Sessions

Avg Cost

Dropout

Indiv. (N=6.061)

9.76 (13.44)b

$497.57 ($779.03)b

15.34%a

Family (N=529)

5.49 (9.64)

$292.79 ($545.50)

29.50%

Mixed (N=1.161)

17.14 (18.88)b $848.25 ($1099.38)b

N/A

MDs (N=405)

6.66 (12.13)a

$399.80 ($663.32)

38.52%b

RNs (N=60)

9.02 (12.40)

$451.90 (637.11)

16.67%

PSYs (N=1,913)

11.91 (16.22)b $664.82 ($996.42)b

11.76%a

LPCs (N=1,610)

9.18 (11.00)

$428.42 (590.13)

13.60%

MSWs (N=2,667)

11.01 (15.05)

$510.35 ($743.63)

12.60%

MFTs (N=531)

10.03 (13.62)

$481.22 ($786.33)

12.99%

Mild (N=695)

9.35 (11.45)

$473.46 (640.72)

16.12%

Moderate (N=3,532)

10.29 (13.89)

$517.11 ($764.03)

14.69%

Severe (N=2,457)

10.94 (14.99)b $559.20 ($875.19)b

12.54%a

Severe w/ (N=1,067)

11.46 (16.75)b $586.71 (1,040.91)b

14.15%

Total (N=7,751)

10.57 (14.48)

14.06%

$542.29 ($850.43)

a

indicates a value significantly lower than the control groups (Family therapy, MFT, mild)

b

indicates a value significantly higher than the control groups (Family therapy, MFT, mild)
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Table 3
Regression results for MDD, unstandardized coefficients with standard errors in parentheses
(1)
cost

(2)
Sessions

(3)
dropout

DP-Moderate

30.85***
(6.53)

0.58***
(0.12)

-0.05
(0.03)

DP-Severe w/out

67.53***
(6.91)

1.28***
(0.13)

-0.07*
(0.03)

DP-Severe w/Psych.

79.59***
(14.54)

1.55***
(0.26)

-0.03
(0.06)

LPC

-3.70
(8.07)

-0.12
(0.15)

-0.06
(0.04)

MD

-1.69
(14.46)

-2.58***
(0.26)

0.89***
(0.05)

RN

22.72
(20.03)

-0.92*
(0.36)

0.13
(0.08)

MSW

10.32
(7.47)

0.33*
(0.14)

-0.06
(0.03)

PSY

144.44***
(7.53)

1.13***
(0.14)

-0.17***
(0.03)

IT

132.15***
(8.14)

2.87***
(0.15)

-0.46***
(0.03)

MT

455.41***
(9.38)

9.55***
(0.17)

-4.22***
(0.12)

Constant

91.69***
(13.71)
120330

1.45***
(0.25)
120329

-0.81***
(0.06)
120330

Observations
Standard errors in parentheses
*
p < 0.05, ** p < 0.01, *** p < 0.001
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Table 4
Regressions results for BD, unstandardized coefficients with standard errors in parentheses
(1)
cost

(2)
Sessions

(3)
dropout

BP-Moderate

37.03
(33.04)

0.83
(0.60)

-0.13
(0.12)

BP-Severe w/out

78.67*
(34.22)

1.53*
(0.62)

-0.36**
(0.13)

BP-Severe w/Psych.

92.24*
(38.96)

1.93**
(0.70)

-0.25
(0.15)

LPC

6.01
(39.93)

0.10
(0.72)

0.00
(0.16)

MD

-32.61
(52.97)

-2.07*
(0.96)

1.31***
(0.18)

RN

13.87
(105.20)

-0.24
(1.90)

0.26
(0.38)

MSW

42.91
(38.01)

1.29
(0.69)

-0.01
(0.15)

PSY

202.58***
(38.57)

2.25**
(0.70)

-0.11
(0.15)

IT

111.17**
(37.14)

2.49***
(0.67)

-0.51***
(0.11)

MT

483.32***
(42.51)

10.36***
(0.77)

-4.43***
(0.51)

48.34
(65.54)
7180

0.09
(1.18)
7180

-0.89***
(0.24)
7180

Constant
Observations
Standard errors in parentheses
*
p < 0.05, ** p < 0.01, *** p < 0.001

